Paper Details

  1. Home
  2. Paper Details

Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.

Author: AlonsoGuzmán, BarkerScott S, Bence LinAimee, BesseBenjamin, DrilonAlexander, GautschiOliver, GotoKoichi, LoongHerbert, ParkKeunchil, PuriTarun, Shao-Weng TanDaniel, SoldatenkovaVictoria, SolomonBenjamin J, SubbiahVivek, SzymczakSylwia, TomasiniPascale, WolfJürgen, de BraudFilippo

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.

Overview

This article provides an update on the registrational data for selpercatinib, a selective RET kinase inhibitor for patients with RET fusion-positive non-small-cell lung cancer (NSCLC). The data set is expanded to include over double the original population, offering better characterization of long-term efficacy and safety.
Paper Details　
Original Abstract of the Article :
Label="PURPOSE">Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase inhibitor, is currently approved for the treatment of patients with <i>RET</i> fusion-positive non-small-cell lung cancer (NSCLC). We provide a registrational data set update in more than double (n = ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839260/

データ提供：米国国立医学図書館（NLM）

Selpercatinib: A New Hope for RET Fusion-Positive Lung Cancer

Lung cancer is a leading cause of death worldwide, and the search for effective treatments continues to be a priority for researchers. This study explores the efficacy and safety of selpercatinib, a novel RET kinase inhibitor, in patients with RET fusion-positive non-small-cell lung cancer (NSCLC). Researchers conducted a phase I/II clinical trial to evaluate the drug's effectiveness and identify potential side effects.

The study found that selpercatinib demonstrated significant efficacy in treating RET fusion-positive NSCLC, showing a high response rate and durable responses. The researchers also observed a manageable safety profile, with the most common side effects being fatigue, diarrhea, and nausea. This study provides strong evidence for the potential of selpercatinib as a valuable new treatment option for this specific type of lung cancer.

A New Weapon in the Fight Against Lung Cancer

This study offers a glimmer of hope in the fight against lung cancer, showcasing the promise of selpercatinib as a targeted therapy for RET fusion-positive NSCLC. The findings highlight the importance of personalized medicine approaches in cancer treatment, focusing on specific genetic alterations to develop more effective and targeted therapies.

Navigating the Complexities of Lung Cancer Treatment

Lung cancer is a complex and challenging disease, requiring a multifaceted approach to treatment. This study highlights the potential of targeted therapies, like selpercatinib, in addressing the unique characteristics of specific lung cancer subtypes, leading to more effective and personalized treatment strategies.

Dr. Camel's Conclusion

The search for effective lung cancer treatments is a journey across a vast desert of challenges. This study presents selpercatinib as a potential oasis, offering hope for a more effective and targeted therapy for RET fusion-positive NSCLC. By understanding the specific genetic alterations driving this type of cancer, we can develop more personalized and effective treatment strategies, providing hope for a brighter future for those affected by this disease.

Date :
  1. Date Completed 2023-01-09
  2. Date Revised 2023-11-15
Further Info :

Pubmed ID

36122315

DOI: Digital Object Identifier

PMC9839260

Related Literature

Article Analysis
・Effects of selpercatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.